135 related articles for article (PubMed ID: 33843428)
1. SPAG6-silencing enhances decitabine-induced apoptosis and demethylation of PTEN in SKM-1 cells and in a xenograft mouse model.
Luo J; Mu J; Zhang M; Zhao B; Liu L
Leuk Lymphoma; 2021 Sep; 62(9):2242-2252. PubMed ID: 33843428
[TBL] [Abstract][Full Text] [Related]
2. [Effects of SPAG6 silencing and decitabine treatment on apoptosis and phosphatase and tensin homolog methylation in SKM-1 cells].
Luo J; Mu J; Liu L
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):1005-1010. PubMed ID: 35045671
[No Abstract] [Full Text] [Related]
3. SPAG6 silencing induces apoptosis in the myelodysplastic syndrome cell line SKM‑1 via the PTEN/PI3K/AKT signaling pathway in vitro and in vivo.
Yin J; Li X; Zhang Z; Luo X; Wang L; Liu L
Int J Oncol; 2018 Jul; 53(1):297-306. PubMed ID: 29749435
[TBL] [Abstract][Full Text] [Related]
4. SPAG6 silencing inhibits the growth of the malignant myeloid cell lines SKM-1 and K562 via activating p53 and caspase activation-dependent apoptosis.
Yang B; Wang L; Luo X; Chen L; Yang Z; Liu L
Int J Oncol; 2015 Feb; 46(2):649-56. PubMed ID: 25405588
[TBL] [Abstract][Full Text] [Related]
5. SPAG6 silencing induces autophagic cell death in SKM-1 cells via the AMPK/mTOR/ULK1 signaling pathway.
Zhang M; Luo J; Luo X; Liu L
Oncol Lett; 2020 Jul; 20(1):551-560. PubMed ID: 32537026
[TBL] [Abstract][Full Text] [Related]
6. SPAG6 regulates cell apoptosis through the TRAIL signal pathway in myelodysplastic syndromes.
Li X; Yang B; Wang L; Chen L; Luo X; Liu L
Oncol Rep; 2017 May; 37(5):2839-2846. PubMed ID: 28393201
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of
Jiang M; Chen Y; Deng L; Luo X; Wang L; Liu L
DNA Cell Biol; 2019 May; 38(5):476-484. PubMed ID: 30835546
[TBL] [Abstract][Full Text] [Related]
8. [Functional study of hENT1 on SKM-1 cell resistance to decitabine].
Shi W; Wu L; Guo J; Xu F; Chang C; Li X
Zhonghua Xue Ye Xue Za Zhi; 2015 May; 36(5):408-12. PubMed ID: 26031529
[TBL] [Abstract][Full Text] [Related]
9. SPAG6 promotes cell proliferation and inhibits apoptosis through the PTEN/PI3K/AKT pathway in Burkitt lymphoma.
Zhang R; Zhu H; Yuan Y; Wang Y; Tian Z
Oncol Rep; 2020 Nov; 44(5):2021-2030. PubMed ID: 33000212
[TBL] [Abstract][Full Text] [Related]
10. Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
Geng S; Yao H; Weng J; Tong J; Huang X; Wu P; Deng C; Li M; Lu Z; Du X
Leuk Res; 2016 May; 44():17-24. PubMed ID: 26991610
[TBL] [Abstract][Full Text] [Related]
11. Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation.
Zeng W; Dai H; Yan M; Cai X; Luo H; Ke M; Liu Z
J Immunol Res; 2017; 2017():4302320. PubMed ID: 29124072
[TBL] [Abstract][Full Text] [Related]
12. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Huang L; Liu Z; Jiang H; Li L; Fu R
J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of HO-1 promoted apoptosis induced by decitabine via increasing p15INK4B promoter demethylation in myelodysplastic syndrome.
Ma D; Fang Q; Wang P; Gao R; Sun J; Li Y; Hu XY; Wang JS
Gene Ther; 2015 Apr; 22(4):287-96. PubMed ID: 25652099
[TBL] [Abstract][Full Text] [Related]
14. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Silencing of
Lee P; Yim R; Miu KK; Fung SH; Liao JJ; Wang Z; Li J; Yung Y; Chu HT; Yip PK; Lee E; Tse E; Kwong YL; Gill H
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628480
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Yisui granule on myelodysplastic syndromes in SKM-1 mouse xenograft model through suppressing Wnt/β-catenin signaling pathway.
Jieya WU; Li H; Xiaoyuan Z; Gullen E; Chong G; Jing W
J Tradit Chin Med; 2024 Feb; 44(1):78-87. PubMed ID: 38213242
[TBL] [Abstract][Full Text] [Related]
17. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
Wu L; Shi W; Li X; Chang C; Xu F; He Q; Wu D; Su J; Zhou L; Song L; Xiao C; Zhang Z
J Transl Med; 2016 Mar; 14():66. PubMed ID: 26944860
[TBL] [Abstract][Full Text] [Related]
18. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
19. Silencing HO-1 sensitizes SKM-1 cells to apoptosis induced by low concentration 5-azacytidine through enhancing p16 demethylation.
Wang P; Ma D; Wang J; Fang Q; Gao R; Wu W; Lu T; Cao L
Int J Oncol; 2015 Mar; 46(3):1317-27. PubMed ID: 25585641
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
Hu N; Qin T; Du X; Wang B; Wang X; Xu Z; Pan L; Qu S; Xiao Z
Med Sci Monit; 2021 Jan; 27():e928454. PubMed ID: 33514682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
